Das Zentrum
Multiple Sklerose Zentrum Dresden
Patienteninformation
Kontaktinformation
Behandlungsteam
Studienteam
Neuropsychologie
Mobilitätszentrum
Das Mobilitätszentrum
Ganganalyse
Sprunganalyse
DIERS
EMIQ
Forschungsprojekte
Neuroimmunologisches Labor
Das NIL
Neurofilament-Leichtketten Analyse
Autonomes & Neuroendokrinologisches Funktionslabor
Das ANF
Untersuchungsmethoden
MS Living Lab
Management & Science
Team Management & Science
Projekte
eHealth & Analytics
MSDS 3D
MSDS Klinik & Praxis
MS-HRS
MTRS
MS Management
Aktuelles
Neuigkeiten
Publikationen
Veranstaltungen
Adventssymposium
Multiple Sklerose 360°
Welt-MS-Tag 2021
Doktorarbeiten
Jobs
Kontakt
Podcasts & Newsletter
Newsletter
Patienten-Podcast
Ärzte-Podcast
Studien
Interventionelle Studien
B-SHUTTLE
Nicht-interventionelle Studien
MS PATHS
Konectom
Sprachanalyse
Deutsch
Deutsch
English (UK)
Real-world evidence from Germany and the United States: Treatment initiation on low-efficacy versus high-efficacy therapies in patients with multiple sclerosis
MS Treatments
Jahr
Publikationsjahr
2024
Autoren
Autorenliste der Publikation
Papukchieva S, Kim HD, Stratil AS, Magurne E, Jonckheere A, Kahn M, Schneeweiss S, Ziemssen T, Friedrich B.
Verlag
Publisher-Information
Mult Scler Relat Disord. 2024 Jul 4;88:105751.
Link
Zur Publikation (externer Server)
https://doi.org/10.1016/j.msard.2024.105751
Tags
Forschungsthemen
Multiple Sklerose
MS Behandlung
Management & Science
MSZ
Treatments
MASC
2024
Raman Spectroscopy of Optically Trapped Living Human T Cell Subsets and Monocytes
NIL
Jahr
2024
COVID-19 and multiple sclerosis: challenges and lessons for patient care
Multiple Sclerosis
Jahr
2024
A future of AI-driven personalized care for people with multiple sclerosis
MASC
Jahr
2024
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374
NIL
Jahr
2024
Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons
MS Treatments
Jahr
2024
